Gilead Sciences Inc. (GILD)
Analysis of Profitability Ratios
Quarterly Data
Beginner level
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Gilead Sciences Inc., profitability ratios (quarterly data)
Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Gilead Sciences Inc.’s gross profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Gilead Sciences Inc.’s operating profit margin ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Gilead Sciences Inc.’s net profit margin ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Gilead Sciences Inc.’s ROE deteriorated from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Gilead Sciences Inc.’s ROA improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019. |
Gross Profit Margin
Gilead Sciences Inc., gross profit margin calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Gross profit on product sales | 4,481 | 4,607 | 4,243 | 4,111 | 4,369 | 4,344 | 4,000 | 4,581 | 5,370 | 5,920 | 5,420 | 6,141 | 6,276 | 6,787 | 6,488 | 7,347 | 7,147 | 7,128 | 6,523 | 6,159 | 4,981 | 5,488 | 4,058 | |
| Product sales | 5,516 | 5,607 | 5,200 | 5,681 | 5,455 | 5,540 | 5,001 | 5,837 | 6,402 | 7,046 | 6,377 | 7,216 | 7,405 | 7,651 | 7,681 | 8,409 | 8,211 | 8,126 | 7,405 | 7,222 | 5,968 | 6,413 | 4,871 | |
| Profitability Ratio | ||||||||||||||||||||||||
| Gross profit margin1 | 79.27% | 78.98% | 78.02% | 77.61% | 79.21% | 80.31% | 81.82% | 82.97% | 84.51% | 84.71% | 85.95% | 85.77% | 86.36% | 86.91% | 86.69% | 87.54% | 87.06% | 86.32% | 85.72% | 84.52% | — | — | — | |
| Benchmarks | ||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 52.39% | 52.17% | 51.57% | 51.32% | 50.57% | 50.38% | 49.39% | 47.75% | 48.59% | 49.21% | 51.32% | 54.09% | 54.17% | 53.99% | 53.93% | 54.19% | 53.83% | 53.39% | 52.87% | 51.73% | — | — | — | |
| AbbVie Inc. | 77.32% | 77.41% | 77.07% | 76.44% | 75.22% | 74.93% | 75.18% | 75.05% | 76.85% | 76.78% | 76.81% | 77.25% | 77.21% | 78.12% | 79.28% | 80.31% | 81.09% | 80.60% | 79.12% | 77.83% | — | — | — | |
| Allergan PLC | 84.96% | 85.09% | 86.21% | 86.12% | 86.39% | 86.56% | 86.03% | 86.40% | 86.65% | 87.11% | 87.56% | 87.23% | 86.55% | 81.36% | 73.17% | 68.08% | 62.19% | 57.25% | 53.50% | 51.74% | — | — | — | |
| Amgen Inc. | 81.19% | 81.23% | 81.26% | 81.80% | 81.61% | 81.78% | 81.69% | 81.33% | 81.37% | 81.26% | 81.05% | 80.99% | 80.68% | 80.64% | 80.23% | 79.82% | 79.13% | 78.27% | 78.00% | 77.12% | — | — | — | |
| Biogen Inc. | 85.97% | 85.59% | 85.72% | 86.50% | 86.12% | 86.43% | 86.57% | 86.72% | 87.34% | 86.80% | 86.56% | 87.08% | 87.46% | 88.21% | 88.65% | 88.48% | 88.59% | 88.36% | 88.11% | 87.93% | — | — | — | |
| Bristol-Myers Squibb Co. | 69.65% | 69.93% | 70.77% | 70.98% | 70.37% | 70.12% | 69.62% | 70.80% | 71.92% | 72.78% | 74.19% | 74.54% | 75.56% | 75.55% | 75.67% | 76.39% | 76.27% | 76.60% | 76.34% | 75.24% | — | — | — | |
| Eli Lilly & Co. | 77.78% | 76.67% | 74.96% | 73.81% | 73.39% | 72.92% | 72.95% | 73.46% | 73.69% | 73.89% | 73.78% | 73.35% | 73.23% | 73.72% | 74.39% | 74.76% | 75.13% | 74.87% | 74.96% | 74.85% | — | — | — | |
| Johnson & Johnson | 66.49% | 66.67% | 66.80% | 66.79% | 66.36% | 65.69% | 66.22% | 66.84% | 68.20% | 69.35% | 69.88% | 69.84% | 69.52% | 69.58% | 69.25% | 69.27% | 69.20% | 69.55% | 69.33% | 69.40% | — | — | — | |
| Merck & Co. Inc. | 70.13% | 69.89% | 68.94% | 68.06% | 67.35% | 67.81% | 68.22% | 68.16% | 68.09% | 67.92% | 66.61% | 65.10% | 63.89% | 62.58% | 62.07% | 62.19% | 62.70% | 62.00% | 60.30% | 60.30% | — | — | — | |
| Pfizer Inc. | 79.85% | 79.91% | 79.36% | 79.03% | 78.58% | 78.24% | 78.48% | 78.61% | 78.66% | 78.15% | 77.28% | 76.66% | 76.48% | 77.71% | 79.09% | 80.25% | 81.35% | 81.14% | 80.92% | 80.69% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 91.14% | 92.27% | 92.79% | 93.53% | 93.36% | 93.28% | 92.95% | 93.24% | 93.37% | 94.16% | 94.53% | 93.83% | 92.90% | 91.38% | 90.52% | 90.43% | 91.04% | 91.52% | 91.99% | 92.73% | — | — | — | |
Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).
1 Q3 2019 Calculation
Gross profit margin = 100
× (Gross profit on product salesQ3 2019
+ Gross profit on product salesQ2 2019
+ Gross profit on product salesQ1 2019
+ Gross profit on product salesQ4 2018)
÷ (Product salesQ3 2019
+ Product salesQ2 2019
+ Product salesQ1 2019
+ Product salesQ4 2018)
= 100
× (4,481 + 4,607 + 4,243 + 4,111)
÷ (5,516 + 5,607 + 5,200 + 5,681)
= 79.27%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Gilead Sciences Inc.’s gross profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
Operating Profit Margin
Gilead Sciences Inc., operating profit margin calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Income (loss) from operations | (1,473) | 2,430 | 2,237 | 1,144 | 2,623 | 2,280 | 2,153 | 2,291 | 3,812 | 4,254 | 3,767 | 4,045 | 4,399 | 4,538 | 4,651 | 5,621 | 5,585 | 5,616 | 5,371 | 4,330 | 3,479 | 4,413 | 3,043 | |
| Product sales | 5,516 | 5,607 | 5,200 | 5,681 | 5,455 | 5,540 | 5,001 | 5,837 | 6,402 | 7,046 | 6,377 | 7,216 | 7,405 | 7,651 | 7,681 | 8,409 | 8,211 | 8,126 | 7,405 | 7,222 | 5,968 | 6,413 | 4,871 | |
| Profitability Ratio | ||||||||||||||||||||||||
| Operating profit margin1 | 19.71% | 38.44% | 37.87% | 37.83% | 42.81% | 46.25% | 51.51% | 55.04% | 58.72% | 58.71% | 58.46% | 58.87% | 61.67% | 63.83% | 66.22% | 69.03% | 67.51% | 65.45% | 65.14% | 62.37% | — | — | — | |
| Benchmarks | ||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 13.74% | 13.27% | 12.31% | 11.94% | 10.45% | 10.11% | 8.92% | 6.30% | 7.89% | 8.77% | 11.03% | 15.27% | 14.74% | 13.95% | 13.64% | 14.05% | 14.00% | 14.13% | 13.95% | 12.84% | — | — | — | |
| AbbVie Inc. | 20.04% | 21.85% | 19.88% | 19.49% | 32.99% | 32.84% | 34.03% | 33.99% | 37.24% | 36.74% | 36.33% | 36.60% | 36.21% | 35.00% | 34.18% | 32.97% | 22.86% | 19.46% | 18.33% | 17.09% | — | — | — | |
| Allergan PLC | -60.39% | -55.48% | -50.30% | -39.57% | -5.95% | -32.39% | -35.34% | -37.15% | -43.48% | -19.74% | -17.36% | -12.53% | -13.13% | -20.47% | -15.77% | -20.00% | -17.09% | -15.71% | -16.60% | -9.71% | — | — | — | |
| Amgen Inc. | 44.83% | 44.05% | 44.53% | 45.55% | 45.82% | 46.46% | 46.07% | 45.76% | 46.66% | 46.93% | 45.68% | 44.74% | 43.33% | 42.46% | 41.53% | 40.44% | 37.98% | 34.90% | 34.51% | 32.03% | — | — | — | |
| Biogen Inc. | 47.13% | 46.90% | 42.40% | 43.77% | 44.67% | 45.58% | 46.49% | 43.54% | 40.25% | 38.72% | 41.59% | 44.99% | 47.59% | 47.86% | 47.11% | 45.44% | 46.21% | 45.28% | 43.63% | 40.94% | — | — | — | |
| Bristol-Myers Squibb Co. | 28.64% | 28.60% | 23.44% | 22.69% | 18.64% | 15.93% | 17.50% | 17.39% | 19.71% | 21.73% | 24.06% | 23.83% | 19.21% | 16.34% | 11.09% | 11.41% | 16.40% | 16.96% | 18.39% | 16.32% | — | — | — | |
| Eli Lilly & Co. | 20.00% | 19.48% | 12.50% | 15.15% | 12.34% | 9.11% | 14.88% | 9.38% | 12.43% | 14.23% | 12.92% | 16.30% | 14.31% | 14.56% | 14.27% | 13.47% | 13.53% | 11.55% | 12.00% | 13.56% | — | — | — | |
| Johnson & Johnson | 24.15% | 22.63% | 22.69% | 24.27% | 22.59% | 23.05% | 23.63% | 24.07% | 27.02% | 28.55% | 28.83% | 28.72% | 26.37% | 25.66% | 25.00% | 25.05% | 26.50% | 27.31% | 28.10% | 28.20% | — | — | — | |
| Merck & Co. Inc. | 25.56% | 26.73% | 24.38% | 19.62% | 17.84% | 12.28% | 13.57% | 16.28% | 9.92% | 16.85% | 14.45% | 13.51% | 19.60% | 18.10% | 18.19% | 17.54% | 16.06% | 13.62% | 12.51% | 13.42% | — | — | — | |
| Pfizer Inc. | 26.30% | 27.50% | 26.86% | 26.10% | 26.18% | 26.00% | 25.86% | 25.92% | 24.69% | 23.57% | 22.94% | 22.73% | 22.96% | 24.02% | 24.86% | 24.20% | 25.33% | 25.85% | 26.09% | 26.71% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 29.55% | 29.58% | 35.41% | 37.77% | 37.00% | 36.89% | 36.54% | 35.41% | 34.22% | 32.29% | 28.76% | 27.38% | 25.67% | 26.77% | 29.26% | 30.51% | 33.30% | 31.17% | 30.56% | 29.74% | — | — | — | |
Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).
1 Q3 2019 Calculation
Operating profit margin = 100
× (Income (loss) from operationsQ3 2019
+ Income (loss) from operationsQ2 2019
+ Income (loss) from operationsQ1 2019
+ Income (loss) from operationsQ4 2018)
÷ (Product salesQ3 2019
+ Product salesQ2 2019
+ Product salesQ1 2019
+ Product salesQ4 2018)
= 100 × (-1,473 + 2,430 + 2,237 + 1,144)
÷ (5,516 + 5,607 + 5,200 + 5,681)
= 19.71%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Gilead Sciences Inc.’s operating profit margin ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019. |
Net Profit Margin
Gilead Sciences Inc., net profit margin calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Net income (loss) attributable to Gilead | (1,165) | 1,880 | 1,975 | 3 | 2,097 | 1,817 | 1,538 | (3,865) | 2,718 | 3,073 | 2,702 | 3,108 | 3,330 | 3,497 | 3,566 | 4,683 | 4,600 | 4,492 | 4,333 | 3,487 | 2,731 | 3,656 | 2,227 | |
| Product sales | 5,516 | 5,607 | 5,200 | 5,681 | 5,455 | 5,540 | 5,001 | 5,837 | 6,402 | 7,046 | 6,377 | 7,216 | 7,405 | 7,651 | 7,681 | 8,409 | 8,211 | 8,126 | 7,405 | 7,222 | 5,968 | 6,413 | 4,871 | |
| Profitability Ratio | ||||||||||||||||||||||||
| Net profit margin1 | 12.24% | 27.14% | 26.93% | 25.16% | 7.27% | 9.69% | 14.26% | 18.03% | 42.90% | 43.55% | 44.11% | 45.07% | 48.40% | 51.16% | 53.48% | 56.32% | 54.62% | 52.38% | 52.60% | 49.44% | — | — | — | |
| Benchmarks | ||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 10.50% | 9.36% | 8.53% | 7.74% | 2.91% | 3.13% | 1.67% | 1.74% | 8.37% | 4.96% | 6.74% | 6.71% | 6.61% | 11.08% | 12.00% | 21.68% | 22.17% | 22.04% | 20.60% | 11.28% | — | — | — | |
| AbbVie Inc. | 9.90% | 12.62% | 16.42% | 17.36% | 23.50% | 20.84% | 21.55% | 18.82% | 24.38% | 24.77% | 24.07% | 23.22% | 24.08% | 23.11% | 23.03% | 22.50% | 12.86% | 9.93% | 8.89% | 8.89% | — | — | — | |
| Allergan PLC | -58.50% | -54.25% | -45.94% | -32.28% | 14.50% | -9.86% | -11.51% | -25.88% | -46.82% | 79.17% | 82.42% | 102.76% | 107.27% | 31.97% | 29.44% | 25.98% | 23.16% | -15.76% | -17.26% | -12.48% | — | — | — | |
| Amgen Inc. | 36.14% | 35.57% | 35.93% | 37.25% | 9.96% | 10.72% | 10.11% | 9.08% | 37.36% | 37.24% | 36.12% | 35.27% | 35.19% | 34.48% | 33.86% | 33.13% | 30.94% | 28.90% | 28.76% | 26.69% | — | — | — | |
| Biogen Inc. | 37.91% | 37.62% | 33.79% | 32.93% | 24.08% | 23.06% | 23.54% | 20.69% | 29.44% | 28.10% | 30.17% | 32.34% | 34.03% | 33.97% | 33.79% | 32.95% | 34.06% | 33.89% | 32.36% | 30.25% | — | — | — | |
| Bristol-Myers Squibb Co. | 23.39% | 26.00% | 22.09% | 21.81% | 6.50% | 1.74% | 4.37% | 4.85% | 20.56% | 22.66% | 24.22% | 22.94% | 18.22% | 16.29% | 9.31% | 9.45% | 10.74% | 10.93% | 13.99% | 12.62% | — | — | — | |
| Eli Lilly & Co. | 35.10% | 33.76% | 26.12% | 13.16% | 1.85% | -0.60% | 4.82% | -0.89% | 9.90% | 11.12% | 10.13% | 12.90% | 11.73% | 11.97% | 11.49% | 12.07% | 11.97% | 10.50% | 11.20% | 12.19% | — | — | — | |
| Johnson & Johnson | 17.32% | 20.08% | 17.99% | 18.75% | 1.89% | 1.70% | 1.58% | 1.70% | 21.28% | 22.52% | 22.87% | 23.01% | 22.27% | 21.20% | 22.15% | 21.99% | 20.87% | 22.41% | 21.63% | 21.96% | — | — | — | |
| Merck & Co. Inc. | 20.26% | 21.10% | 19.50% | 14.71% | 8.02% | 3.25% | 3.88% | 5.97% | 7.15% | 12.71% | 10.88% | 9.85% | 13.76% | 13.01% | 11.72% | 11.25% | 27.11% | 24.48% | 26.98% | 28.22% | — | — | — | |
| Pfizer Inc. | 30.57% | 23.58% | 21.31% | 20.79% | 44.63% | 42.35% | 41.29% | 40.55% | 18.69% | 15.90% | 13.88% | 13.66% | 11.77% | 13.47% | 14.95% | 14.25% | 17.45% | 18.46% | 18.69% | 18.42% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 28.13% | 28.59% | 35.12% | 36.42% | 28.24% | 25.65% | 23.54% | 20.41% | 23.17% | 22.05% | 19.34% | 18.42% | 16.85% | 15.98% | 16.72% | 15.50% | 15.53% | 13.56% | 11.71% | 12.34% | — | — | — | |
Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).
1 Q3 2019 Calculation
Net profit margin = 100
× (Net income (loss) attributable to GileadQ3 2019
+ Net income (loss) attributable to GileadQ2 2019
+ Net income (loss) attributable to GileadQ1 2019
+ Net income (loss) attributable to GileadQ4 2018)
÷ (Product salesQ3 2019
+ Product salesQ2 2019
+ Product salesQ1 2019
+ Product salesQ4 2018)
= 100 × (-1,165 + 1,880 + 1,975 + 3)
÷ (5,516 + 5,607 + 5,200 + 5,681)
= 12.24%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Gilead Sciences Inc.’s net profit margin ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019. |
Return on Equity (ROE)
Gilead Sciences Inc., ROE calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Net income (loss) attributable to Gilead | (1,165) | 1,880 | 1,975 | 3 | 2,097 | 1,817 | 1,538 | (3,865) | 2,718 | 3,073 | 2,702 | 3,108 | 3,330 | 3,497 | 3,566 | 4,683 | 4,600 | 4,492 | 4,333 | 3,487 | 2,731 | 3,656 | 2,227 | |
| Total Gilead stockholders’ equity | 20,604 | 22,616 | 21,951 | 21,387 | 22,861 | 21,672 | 20,591 | 20,442 | 24,845 | 22,677 | 20,441 | 18,887 | 16,868 | 15,536 | 13,398 | 18,534 | 17,414 | 16,287 | 17,180 | 15,426 | 13,566 | 16,091 | 13,387 | |
| Profitability Ratio | ||||||||||||||||||||||||
| ROE1 | 13.07% | 26.33% | 26.84% | 25.51% | 6.94% | 10.19% | 16.82% | 22.64% | 46.69% | 53.86% | 61.82% | 71.48% | 89.38% | 105.21% | 129.43% | 97.70% | 97.12% | 92.36% | 82.69% | 78.45% | — | — | — | |
| Benchmarks | ||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 10.35% | 9.14% | 8.48% | 7.76% | 2.89% | 3.03% | 1.52% | 1.54% | 6.57% | 3.71% | 4.79% | 6.82% | 6.59% | 11.02% | 11.81% | 20.85% | 21.60% | 19.64% | 19.21% | 10.61% | — | — | — | |
| AbbVie Inc. | — | — | — | — | — | — | 179.59% | 104.16% | 99.42% | 110.08% | 126.25% | 128.41% | 93.97% | 101.42% | 117.94% | 130.39% | 57.93% | 37.86% | 131.88% | 101.84% | — | — | — | |
| Allergan PLC | -15.82% | -14.25% | -11.73% | -7.83% | 3.30% | -2.24% | -2.55% | -5.59% | -10.18% | 15.86% | 16.16% | 19.65% | 15.99% | 5.77% | 6.05% | 5.11% | 4.92% | -3.51% | -3.14% | -5.76% | — | — | — | |
| Amgen Inc. | 73.83% | 73.73% | 74.55% | 67.15% | 15.35% | 15.86% | 14.21% | 7.84% | 25.37% | 25.77% | 25.76% | 25.85% | 24.65% | 24.67% | 25.16% | 24.71% | 23.00% | 21.15% | 21.53% | 20.01% | — | — | — | |
| Biogen Inc. | 38.55% | 40.87% | 33.74% | 33.98% | 23.15% | 24.21% | 21.09% | 20.13% | 27.10% | 28.42% | 30.31% | 30.50% | 32.06% | 33.48% | 35.78% | 37.84% | 34.04% | 27.76% | 28.09% | 27.15% | — | — | — | |
| Bristol-Myers Squibb Co. | 32.04% | 38.65% | 33.80% | 35.07% | 10.50% | 3.05% | 7.18% | 8.58% | 28.61% | 31.20% | 33.55% | 27.55% | 21.56% | 19.24% | 10.94% | 10.97% | 11.77% | 11.84% | 14.49% | 13.49% | — | — | — | |
| Eli Lilly & Co. | 234.97% | 282.08% | 252.24% | 32.88% | 3.44% | -1.24% | 7.74% | -1.76% | 14.94% | 17.35% | 15.58% | 19.54% | 15.68% | 16.85% | 15.45% | 16.53% | 15.49% | 14.04% | 14.69% | 15.55% | — | — | — | |
| Johnson & Johnson | 24.31% | 26.87% | 24.90% | 25.60% | 2.39% | 2.18% | 1.97% | 2.16% | 21.39% | 22.71% | 23.46% | 23.49% | 21.91% | 20.73% | 21.40% | 21.66% | 20.56% | 22.64% | 23.45% | 23.40% | — | — | — | |
| Merck & Co. Inc. | 34.70% | 33.88% | 30.50% | 23.30% | 10.32% | 4.12% | 4.69% | 6.97% | 7.44% | 12.89% | 10.91% | 9.78% | 12.55% | 11.84% | 10.53% | 9.94% | 23.65% | 21.21% | 23.38% | 24.50% | — | — | — | |
| Pfizer Inc. | 24.91% | 21.24% | 19.52% | 17.59% | 33.40% | 32.31% | 29.72% | 29.88% | 16.14% | 14.26% | 12.49% | 12.12% | 9.90% | 11.22% | 12.09% | 10.75% | 12.51% | 13.30% | 13.64% | 12.81% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 20.41% | 21.21% | 25.70% | 27.91% | 22.85% | 22.14% | 21.74% | 19.51% | 21.12% | 20.91% | 19.79% | 20.13% | 17.75% | 18.23% | 19.69% | 17.40% | 17.93% | 13.80% | 12.07% | 13.69% | — | — | — | |
Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).
1 Q3 2019 Calculation
ROE = 100
× (Net income (loss) attributable to GileadQ3 2019
+ Net income (loss) attributable to GileadQ2 2019
+ Net income (loss) attributable to GileadQ1 2019
+ Net income (loss) attributable to GileadQ4 2018)
÷ Total Gilead stockholders’ equity
= 100 × (-1,165 + 1,880 + 1,975 + 3)
÷ 20,604 = 13.07%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Gilead Sciences Inc.’s ROE deteriorated from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
Return on Assets (ROA)
Gilead Sciences Inc., ROA calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Net income (loss) attributable to Gilead | (1,165) | 1,880 | 1,975 | 3 | 2,097 | 1,817 | 1,538 | (3,865) | 2,718 | 3,073 | 2,702 | 3,108 | 3,330 | 3,497 | 3,566 | 4,683 | 4,600 | 4,492 | 4,333 | 3,487 | 2,731 | 3,656 | 2,227 | |
| Total assets | 59,146 | 63,210 | 62,837 | 63,675 | 64,305 | 65,355 | 65,381 | 70,283 | 64,662 | 60,263 | 57,701 | 56,977 | 56,609 | 49,980 | 47,765 | 51,839 | 50,637 | 39,167 | 38,321 | 34,664 | 28,844 | 31,206 | 28,078 | |
| Profitability Ratio | ||||||||||||||||||||||||
| ROA1 | 4.55% | 9.42% | 9.38% | 8.57% | 2.47% | 3.38% | 5.30% | 6.58% | 17.94% | 20.27% | 21.90% | 23.70% | 26.63% | 32.71% | 36.30% | 34.93% | 33.40% | 38.41% | 37.07% | 34.91% | — | — | — | |
| Benchmarks | ||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 4.80% | 4.23% | 3.88% | 3.53% | 1.24% | 1.35% | 0.67% | 0.63% | 2.91% | 1.65% | 2.12% | 2.66% | 3.47% | 5.72% | 6.17% | 10.72% | 10.93% | 10.24% | 9.75% | 5.53% | — | — | — | |
| AbbVie Inc. | 5.48% | 7.21% | 9.44% | 9.58% | 11.43% | 10.46% | 9.20% | 7.50% | 9.66% | 9.87% | 9.61% | 9.01% | 9.12% | 8.51% | 10.19% | 9.70% | 5.14% | 3.87% | 6.80% | 6.44% | — | — | — | |
| Allergan PLC | -9.80% | -8.91% | -7.36% | -5.01% | 2.18% | -1.46% | -1.65% | -3.49% | -6.09% | 9.56% | 9.58% | 11.61% | 9.99% | 3.34% | 3.44% | 2.88% | 2.67% | -1.83% | -1.61% | -3.10% | — | — | — | |
| Amgen Inc. | 13.55% | 13.40% | 12.62% | 12.64% | 3.27% | 3.49% | 3.12% | 2.48% | 10.18% | 10.27% | 10.14% | 9.95% | 9.71% | 9.85% | 9.61% | 9.69% | 8.95% | 8.16% | 8.28% | 7.47% | — | — | — | |
| Biogen Inc. | 19.63% | 20.14% | 17.65% | 17.52% | 12.50% | 12.39% | 11.36% | 10.73% | 15.11% | 15.13% | 16.42% | 16.19% | 17.58% | 17.75% | 17.87% | 18.19% | 17.36% | 20.83% | 21.53% | 20.50% | — | — | — | |
| Bristol-Myers Squibb Co. | 9.85% | 11.24% | 14.77% | 14.06% | 4.24% | 1.15% | 2.78% | 3.00% | 12.45% | 13.73% | 14.68% | 13.22% | 9.98% | 8.74% | 4.94% | 4.93% | 5.59% | 5.60% | 6.71% | 5.94% | — | — | — | |
| Eli Lilly & Co. | 20.97% | 20.28% | 16.46% | 7.36% | 1.01% | -0.34% | 2.53% | -0.45% | 5.17% | 5.98% | 5.81% | 7.05% | 6.50% | 6.76% | 6.68% | 6.77% | 6.50% | 5.71% | 6.15% | 6.43% | — | — | — | |
| Johnson & Johnson | 9.10% | 10.53% | 9.78% | 10.00% | 0.99% | 0.88% | 0.79% | 0.83% | 10.17% | 10.69% | 11.39% | 11.71% | 11.36% | 10.75% | 11.41% | 11.55% | 11.04% | 12.20% | 12.38% | 12.45% | — | — | — | |
| Merck & Co. Inc. | 11.18% | 11.15% | 10.20% | 7.53% | 3.93% | 1.58% | 1.84% | 2.72% | 3.11% | 5.48% | 4.50% | 4.11% | 5.58% | 5.32% | 4.67% | 4.36% | 10.65% | 9.60% | 10.31% | 12.12% | — | — | — | |
| Pfizer Inc. | 9.51% | 8.10% | 7.38% | 7.00% | 14.19% | 13.67% | 13.21% | 12.40% | 5.70% | 4.94% | 4.32% | 4.20% | 3.51% | 4.13% | 4.68% | 4.16% | 4.89% | 5.53% | 5.72% | 5.40% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 15.38% | 15.71% | 18.88% | 20.83% | 16.64% | 15.99% | 15.23% | 13.67% | 14.69% | 14.24% | 12.32% | 12.84% | 11.68% | 11.97% | 12.56% | 11.34% | 11.41% | 10.17% | 8.54% | 8.99% | — | — | — | |
Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).
1 Q3 2019 Calculation
ROA = 100
× (Net income (loss) attributable to GileadQ3 2019
+ Net income (loss) attributable to GileadQ2 2019
+ Net income (loss) attributable to GileadQ1 2019
+ Net income (loss) attributable to GileadQ4 2018)
÷ Total assets
= 100 × (-1,165 + 1,880 + 1,975 + 3)
÷ 59,146 = 4.55%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Gilead Sciences Inc.’s ROA improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019. |